Author: admin

DelveInsight’s “Radiation Induced Esophagitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Radiation Induced Esophagitis, historical and forecasted epidemiology as well as the Radiation Induced Esophagitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Radiation Induced Esophagitis, offering comprehensive insights into the Radiation Induced Esophagitis revenue trends, prevalence, and treatment landscape. The report delves into key Radiation Induced Esophagitis statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Radiation Induced Esophagitis therapies. Additionally, we cover the landscape of Radiation Induced Esophagitis clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Radiation Induced Esophagitis treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Radiation Induced Esophagitis space.

To Know in detail about the Radiation Induced Esophagitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Radiation Induced Esophagitis Market Forecast

Some of the key facts of the Radiation Induced Esophagitis Market Report: 

• The Radiation Induced Esophagitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In November 2024, Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotech company focused on precision drug delivery for conditions with high unmet needs, has announced further positive clinical results from its RESOLVE Phase 1b/2a trial, assessing the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis (EoE).

• In August 2023, Galera Therapeutics announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning its New Drug Application (NDA) for avasopasem manganese, intended for the treatment of radiotherapy-induced severe oral mucositis (SOM) in head and neck cancer patients undergoing standard-of-care therapy.

• Radiation-induced esophagitis can be categorized into acute and late types. Acute radiation esophagitis occurs within 3 months of therapy, while late radiation esophagitis develops more than 3 months after treatment. Typically, acute cases appear within 2 to 3 weeks following initial treatment, whereas late cases emerge around 6 months later.

• Approximately 5% of patients who underwent radiation therapy at a dose of 60 Gray (Gy) experienced late complications.

• Current treatments for radiation-induced esophagitis primarily aim at managing symptoms, such as pain relief, anti-inflammatory medications, and nutritional support, rather than targeting the root cause of inflammation and damage to the esophageal tissue.

• Key Radiation Induced Esophagitis Companies: Galera Therapeutics, and others

• Key Radiation Induced Esophagitis Therapies: Avasopasem Manganese, and others

• The Radiation Induced Esophagitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Radiation Induced Esophagitis pipeline products will significantly revolutionize the Radiation Induced Esophagitis market dynamics.

• In 2023, there were 60,000 cases of radiation-induced esophagitis across the 7MM, with the United States accounting for approximately 43% of the total cases, representing the highest number of cases.

• Germany had the highest incidence of radiation-induced esophagitis cases among the EU4 and the UK, followed by the UK.

• Individuals over the age of 70 are at a higher risk of developing radiation-induced esophagitis.

• Radiation-induced esophagitis occurs more frequently in women than in men.

Radiation Induced Esophagitis Overview

Radiation-induced esophagitis is inflammation of the esophagus caused by radiation therapy, commonly used in the treatment of cancers such as lung, breast, or head and neck cancers. The radiation damages the lining of the esophagus, leading to symptoms like pain, difficulty swallowing, chest discomfort, and acid reflux. It typically develops during or shortly after radiation treatment and can range from mild irritation to severe complications. Treatment focuses on managing symptoms and preventing further damage, often through medications like anti-inflammatory drugs, pain relievers, and modifications in diet.

Get a Free sample for the Radiation Induced Esophagitis Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/radiation-induced-esophagitis-market-forecast

Radiation Induced Esophagitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Radiation Induced Esophagitis Epidemiology Segmentation:

The Radiation Induced Esophagitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Radiation Induced Esophagitis

• Prevalent Cases of Radiation Induced Esophagitis by severity

• Gender-specific Prevalence of Radiation Induced Esophagitis

• Diagnosed Cases of Episodic and Chronic Radiation Induced Esophagitis

Download the report to understand which factors are driving Radiation Induced Esophagitis epidemiology trends @ Radiation Induced Esophagitis Epidemiology Forecast

Radiation Induced Esophagitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Radiation Induced Esophagitis market or expected to get launched during the study period. The analysis covers Radiation Induced Esophagitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Radiation Induced Esophagitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Radiation Induced Esophagitis Therapies and Key Companies

• Avasopasem Manganese: Galera Therapeutics

Discover more about therapies set to grab major Radiation Induced Esophagitis market share @ Radiation Induced Esophagitis Treatment Landscape

Radiation Induced Esophagitis Market Drivers

• Rising Cancer Incidences

• Advancements in Radiation Therapy

• Growing Focus on Symptom Management

• Approval of New Therapies

• Increased Research Funding

Radiation Induced Esophagitis Market Barriers

• High Treatment Costs:

• Limited Awareness

• Side Effects of Current Treatments

• Lack of Targeted Therapies

• Regulatory Challenges

Scope of the Radiation Induced Esophagitis Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Radiation Induced Esophagitis Companies: Galera Therapeutics, and others

• Key Radiation Induced Esophagitis Therapies: Avasopasem Manganese, and others

• Radiation Induced Esophagitis Therapeutic Assessment: Radiation Induced Esophagitis current marketed and Radiation Induced Esophagitis emerging therapies

• Radiation Induced Esophagitis Market Dynamics: Radiation Induced Esophagitis market drivers and Radiation Induced Esophagitis market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Radiation Induced Esophagitis Unmet Needs, KOL’s views, Analyst’s views, Radiation Induced Esophagitis Market Access and Reimbursement 

To know more about Radiation Induced Esophagitis companies working in the treatment market, visit @ Radiation Induced Esophagitis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Radiation Induced Esophagitis Market Report Introduction

2. Executive Summary for Radiation Induced Esophagitis

3. SWOT analysis of Radiation Induced Esophagitis

4. Radiation Induced Esophagitis Patient Share (%) Overview at a Glance

5. Radiation Induced Esophagitis Market Overview at a Glance

6. Radiation Induced Esophagitis Disease Background and Overview

7. Radiation Induced Esophagitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Radiation Induced Esophagitis 

9. Radiation Induced Esophagitis Current Treatment and Medical Practices

10. Radiation Induced Esophagitis Unmet Needs

11. Radiation Induced Esophagitis Emerging Therapies

12. Radiation Induced Esophagitis Market Outlook

13. Country-Wise Radiation Induced Esophagitis Market Analysis (2019–2032)

14. Radiation Induced Esophagitis Market Access and Reimbursement of Therapies

15. Radiation Induced Esophagitis Market Drivers

16. Radiation Induced Esophagitis Market Barriers

17.  Radiation Induced Esophagitis Appendix

18. Radiation Induced Esophagitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Radiation Induced Esophagitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Galera Therapeutics

DelveInsight’s “Pulmonary Arterial Hypertension Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Pulmonary Arterial Hypertension, historical and forecasted epidemiology as well as the Pulmonary Arterial Hypertension market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Pulmonary Arterial Hypertension market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Pulmonary Arterial Hypertension Market Forecast

Some of the key facts of the Pulmonary Arterial Hypertension Market Report: 

• The Pulmonary Arterial Hypertension market size was valued approximately USD 4,949 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In March 2024, Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has announced today that the U.S. Food and Drug Administration (FDA) has given approval for sotatercept-csrk (U.S. Brand Name: WINREVAIR™, for injection, 45mg, 60mg) for the management of pulmonary arterial hypertension (PAH) in adults. This medication is indicated to enhance exercise capacity, ameliorate World Health Organization (WHO) functional class (FC), and mitigate the risk of clinical worsening events. WINREVAIR had previously received Breakthrough Therapy Designation from the FDA. It represents the first FDA-approved therapy targeting activin signaling inhibition for PAH, offering a novel therapeutic approach by modulating the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation associated with PAH.

• In January 2024, Pulnovo Medical Limited, a globally renowned innovator in medical devices for treating Pulmonary Hypertension (PH) and Heart Failure (HF), has recently achieved Humanitarian Use Device (HUD) designation from the US FDA and approval from China’s National Medical Products Administration (NMPA) for the PADN Catheter and Generator. The PADN technology marks a significant breakthrough in the realm of global interventional pulmonary arterial hypertension (PAH), addressing challenges in PAH interventional therapy 

• In 2022, the Pulmonary Arterial Hypertension treatment market in the US was valued at around USD 3,898.5 million, and it is expected to grow due to rising awareness of the condition and the introduction of new therapies.

• In 2022, the Pulmonary Arterial Hypertension market size in EU4 and the UK was estimated at approximately USD 816.4 million, accounting for nearly 16% of the total market revenue across the 7MM.

• As per DelveInsight’s estimates, Germany had the largest Pulmonary Arterial Hypertension drugs market in EU4 and the UK, reaching around USD 210.3 million in 2022, followed by France at approximately USD 207.9 million. In contrast, Spain had the smallest market in 2023.

• The evolving pipeline for pulmonary arterial hypertension (PAH) includes various treatments such as Sotatercept (MK-7962) from Merck, ralinepag by United Therapeutics, RT234 (vardenafil inhalation powder) developed by Respira Therapeutics, seralutinib (GB002) from Gossamer Bio, YUTREPIA (an inhaled dry powder formulation of treprostinil) created by Liquidia Technologies, and TNX-201 by Tenax Therapeutics. These treatments are anticipated to be introduced and made available throughout the forecast period from 2023 to 2032.

• In 2022, the collective number of existing cases of pulmonary arterial hypertension (PAH) in the 7MM (Seven Major Markets) was estimated to be around 88,100 cases. Over the study duration (2019─2032), it is anticipated that these cases will show a gradual increase, projected to grow at a Compound Annual Growth Rate (CAGR) of 0.4% by 2032

• In the European Union Four (EU4) and the United Kingdom (UK) combined, there were an estimated 19,720 diagnosed cases of pulmonary arterial hypertension (PAH) in 2022. It is anticipated that these diagnosed cases will experience an increase throughout the study period from 2019 to 2032.

• In 2022, Japan recorded an estimated 204 cases of class I, 1,143 occurrences of class II, 901 cases of class III, and 136 cases of class IV pulmonary arterial hypertension (PAH). It is anticipated that these figures will show a decline over the study period from 2019 to 2032.

• Key Pulmonary Arterial Hypertension Companies: Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others   

• Key Pulmonary Arterial Hypertension Therapies: AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others

• The Pulmonary Arterial Hypertension epidemiology based on gender analyzed that females are more affected with Pulmonary Arterial Hypertension than males

• The Pulmonary Arterial Hypertension market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Pulmonary Arterial Hypertension pipeline products will significantly revolutionize the Pulmonary Arterial Hypertension market dynamics.

Pulmonary Arterial Hypertension Overview

When measured by right heart catheterization, pulmonary hypertension (PH) is defined as mean pulmonary artery pressure greater than 25 mm Hg at rest or greater than 30 mm Hg during activity. PH has been classified into five groups by the World Health Organization (WHO) on the basis of shared pathophysiology, clinical presentation, and available treatments.

Get a Free sample for the Pulmonary Arterial Hypertension Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market

Pulmonary Arterial Hypertension Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Pulmonary Arterial Hypertension Epidemiology Segmentation:

The Pulmonary Arterial Hypertension market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Pulmonary Arterial Hypertension

• Prevalent Cases of Pulmonary Arterial Hypertension by severity

• Gender-specific Prevalence of Pulmonary Arterial Hypertension

• Diagnosed Cases of Episodic and Chronic Pulmonary Arterial Hypertension

Download the report to understand which factors are driving Pulmonary Arterial Hypertension epidemiology trends @ Pulmonary Arterial Hypertension Epidemiology Forecast

Pulmonary Arterial Hypertension Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Pulmonary Arterial Hypertension market or expected to get launched during the study period. The analysis covers Pulmonary Arterial Hypertension market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Pulmonary Arterial Hypertension Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Pulmonary Arterial Hypertension Therapies and Key Companies

• AV-101: Aerovate Therapeutics

• LTP001: Novartis

• KER-012: Keros Therapeutics

• TPN171H: Vigonvita Life Sciences

• Treprostinil Palmitil: Insmed Incorporated

• Satralizumab (Genetical Recombination): Chugai Pharmaceutical

• Sotatercept: Merck Sharp & Dohme

• Macitentan: Janssen Pharmaceutical

• ACT-293987: Actelion

• GB002 (seralutinib): Gossamer Bio

• Parenteral Treprostinil: Lung Biotechnology PBC

• Ralinepag: United Therapeutics

• Selonsertib: Gilead Sciences

• Sotatercept: Acceleron Pharma

• ubenimex: Eiger BioPharmaceuticals

• Olaparib: AstraZeneca

Discover more about therapies set to grab major Pulmonary Arterial Hypertension market share @ Pulmonary Arterial Hypertension Treatment Landscape

Pulmonary Arterial Hypertension Market Strengths

• Better understanding of disease pathophysiology and genetics has improved diagnosis and treatment, reducing mortality

• There have been significant developments in the treatment regime leading to the approval of novel therapies and more defined treatment guidelines

Pulmonary Arterial Hypertension Market Opportunities

• Further research on diagnostic and prognostic blood biomarkers in asymptomatic or specific at-risk populations to improve diagnosis and develop novel treatment options

• The increasing prevalence of PAH, along with government support for the development of orphan drugs, provide companies with an excellent opportunity to invest in the PAH market

Scope of the Pulmonary Arterial Hypertension Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Pulmonary Arterial Hypertension Companies: Aerovate Therapeutics, Novartis, Keros Therapeutics, Vigonvita Life Sciences, Insmed Incorporated, Chugai Pharmaceutical, Merck Sharp & Dohme, Janssen Pharmaceutical, Actelion, Gossamer Bio, Lung Biotechnology PBC, United Therapeutics, Gilead Science, Acceleron Pharma, Eiger BioPharmaceuticals, AstraZeneca, and others

• Key Pulmonary Arterial Hypertension Therapies: AV-101, LTP001, KER-012, TPN171H, Treprostinil Palmitil, Satralizumab (Genetical Recombination), Sotatercept, Macitentan, ACT-293987, GB002 (seralutinib), Parenteral Treprostinil, Ralinepag, Selonsertib, Sotatercept, ubenimex, Olaparib, and others

• Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies

• Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Pulmonary Arterial Hypertension Unmet Needs, KOL’s views, Analyst’s views, Pulmonary Arterial Hypertension Market Access and Reimbursement 

To know more about Pulmonary Arterial Hypertension companies working in the treatment market, visit @ Pulmonary Arterial Hypertension Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Pulmonary Arterial Hypertension Market Report Introduction

2. Executive Summary for Pulmonary Arterial Hypertension

3. SWOT analysis of Pulmonary Arterial Hypertension

4. Pulmonary Arterial Hypertension Patient Share (%) Overview at a Glance

5. Pulmonary Arterial Hypertension Market Overview at a Glance

6. Pulmonary Arterial Hypertension Disease Background and Overview

7. Pulmonary Arterial Hypertension Epidemiology and Patient Population

8. Country-Specific Patient Population of Pulmonary Arterial Hypertension 

9. Pulmonary Arterial Hypertension Current Treatment and Medical Practices

10. Pulmonary Arterial Hypertension Unmet Needs

11. Pulmonary Arterial Hypertension Emerging Therapies

12. Pulmonary Arterial Hypertension Market Outlook

13. Country-Wise Pulmonary Arterial Hypertension Market Analysis (2020–2034)

14. Pulmonary Arterial Hypertension Market Access and Reimbursement of Therapies

15. Pulmonary Arterial Hypertension Market Drivers

16. Pulmonary Arterial Hypertension Market Barriers

17.  Pulmonary Arterial Hypertension Appendix

18. Pulmonary Arterial Hypertension Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pulmonary Arterial Hypertension Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Novartis, Insmed Inc, Chugai Pharma, Merck Sharp & Dohme, Janssen Pharma, Aerovate

DelveInsight’s “Prostate Cancer Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Prostate Cancer, historical and forecasted epidemiology as well as the Prostate Cancer market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Prostate Cancer, offering comprehensive insights into the Prostate Cancer revenue trends, prevalence, and treatment landscape. The report delves into key Prostate Cancer statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Prostate Cancer therapies. Additionally, we cover the landscape of Prostate Cancer clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Prostate Cancer treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Prostate Cancer space.

To Know in detail about the Prostate Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Prostate Cancer Market Forecast

Some of the key facts of the Prostate Cancer Market Report: 

• The Prostate Cancer market size was valued ~USD 7,000 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• In October 2024, A study showed that Johnson & Johnson’s Erleada outperformed Astellas and Pfizer’s Xtandi in real-world treatment of metastatic castration-sensitive prostate cancer (mCSPC). While Xtandi previously led the market, analysis of more than 3,700 patients found Erleada reduced the risk of death by 23% over Xtandi after 24 months. At that point, 88% of patients on Erleada remained alive, aligning with findings from the Phase 3 TITAN trial, compared to an 85% survival rate for Xtandi.

• In September 2024, Ipsen reported that the Phase III CONTACT-02 trial evaluating Cabometyx® and atezolizumab for metastatic castration-resistant prostate cancer (mCRPC) showed a modest improvement in overall survival, though it was not statistically significant, while achieving its progression-free survival (PFS) endpoint.

• In September 2024, Foundation Medicine has obtained FDA approval for its FoundationOne®CDx and Liquid CDx as companion diagnostic tools for identifying BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC) patients eligible for treatment with Lynparza®.

• In July 2024, The ARANOTE trial demonstrated that NUBEQA® combined with ADT significantly enhanced radiological progression-free survival (PFS) in patients with metastatic hormone-sensitive, castration-resistant prostate cancer (mHSPC).

• In July 2024, The FDA has awarded fast-track designation to SYNC-T SV-102 for the treatment of metastatic castration-resistant prostate cancer (mCRPC).

• In 2023, the United States accounted for the largest market share for metastatic castration-resistant prostate cancer (mCRPC) and metastatic castration-sensitive prostate cancer (mCSPC) within the 7MM, at 63% and 61%, respectively, with the EU4 and the UK following.

• The current U.S. market for metastatic castration-resistant prostate cancer (mCRPC) includes therapies such as JEVTANA, ZYTIGA, XTANDI, XOFIGO, among others. In 2023, XTANDI held the largest market share, reaching approximately USD 2,800 million.

• Key Prostate Cancer Companies: Bayer, Johnson & Johnson Innovative Medicine (Janssen), Astellas Pharma, Pfizer, Janssen Research & Development/Tesaro, Sanofi, MacroGenics, Candel Therapeutics, Kangpu Biopharmaceuticals, Point Biopharma, AstraZeneca, Essa Pharma, and others

• Key Prostate Cancer Therapies: NUBEQA (darolutamide), ERLEADA (apalutamide), XTANDI (enzalutamide), AKEEGA (niraparib + abiraterone acetate + prednisone), JEVTANA + prednisone, MGC018 (vobramitamab duocarmazine), CAN-2409, KPG-121, 177Lu-PNT2002 (PNT2002), Capivasertib, CAN-2409 + valacyclovir + radiation therapy ± ADT, MGC018, EPI-7386, and others

• The Prostate Cancer market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Prostate Cancer pipeline products will significantly revolutionize the Prostate Cancer market dynamics.

• According to DelveInsight’s estimates, the total prevalent cases of prostate cancer in the 7MM reached approximately 8,241,400 in 2023; however, this number does not represent the treatable population. These cases are expected to grow over the forecast period from 2024 to 2034.

• In 2023, the United States reported the highest prevalence of prostate cancer cases, with around 3,803,500 cases.

• According to estimates, in 2023, the majority of prostate cancer cases in the US were diagnosed in individuals aged 65 to 74, representing nearly 40% of all cases.

• In the US, the total diagnosed prevalent cases of prostate cancer in 2023 were highest in the locally advanced stages (Stage I–III), with more than 903,700 cases. This was followed by cases of biochemical recurrence/progression and metastatic cases.

Prostate Cancer Overview

Prostate cancer is a form of cancer that develops in the prostate, a small gland in men that produces seminal fluid, which nourishes and transports sperm. It typically grows slowly and may initially remain confined to the prostate, where it may not cause serious harm. However, certain types of prostate cancer can be aggressive and spread to other areas of the body, including bones and lymph nodes. Symptoms often include difficulty urinating, pelvic discomfort, and, in advanced cases, bone pain. Early detection through screenings, such as prostate-specific antigen (PSA) tests, can improve treatment outcomes.

Get a Free sample for the Prostate Cancer Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/prostate-cancer-market-insight

Prostate Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Prostate Cancer Epidemiology Segmentation:

The Prostate Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Prostate Cancer

• Prevalent Cases of Prostate Cancer by severity

• Gender-specific Prevalence of Prostate Cancer

• Diagnosed Cases of Episodic and Chronic Prostate Cancer

Download the report to understand which factors are driving Prostate Cancer epidemiology trends @ Prostate Cancer Epidemiology Forecast

Prostate Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Prostate Cancer market or expected to get launched during the study period. The analysis covers Prostate Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.  Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Prostate Cancer Pipeline Development Activities.

It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Prostate Cancer Therapies and Key Companies

• NUBEQA (darolutamide): Bayer

• ERLEADA (apalutamide): Johnson & Johnson Innovative Medicine (Janssen)

• XTANDI (enzalutamide): Astellas Pharma/Pfizer

• AKEEGA (niraparib + abiraterone acetate + prednisone): Janssen Research & Development/Tesaro

• JEVTANA + prednisone: Sanofi

• MGC018 (vobramitamab duocarmazine): MacroGenics

• CAN-2409: Candel Therapeutics

• KPG-121: Kangpu Biopharmaceuticals

• 177Lu-PNT2002 (PNT2002): Point Biopharma

• Capivasertib: AstraZeneca

• CAN-2409 + valacyclovir + radiation therapy ± ADT: Candel Therapeutics

• MGC018: MacroGenics

• EPI-7386: Essa Pharma

Discover more about therapies set to grab major Prostate Cancer market share @ Prostate Cancer Treatment Landscape

Prostate Cancer Market Drivers

• Rising Incidence Rates

• Advancements in Treatment Options

• Increased Awareness and Screening

• Government Initiatives

• Innovative Diagnostic Techniques

Prostate Cancer Market Barriers

• High Treatment Costs

• Regulatory Challenges

• Limited Awareness in Certain Populations

• Adverse Effects of Treatments

• Competition from Alternative Therapies

Scope of the Prostate Cancer Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Prostate Cancer Companies: Bayer, Johnson & Johnson Innovative Medicine (Janssen), Astellas Pharma, Pfizer, Janssen Research & Development/Tesaro, Sanofi, MacroGenics, Candel Therapeutics, Kangpu Biopharmaceuticals, Point Biopharma, AstraZeneca, Essa Pharma, and others

• Key Prostate Cancer Therapies: NUBEQA (darolutamide), ERLEADA (apalutamide), XTANDI (enzalutamide), AKEEGA (niraparib + abiraterone acetate + prednisone), JEVTANA + prednisone, MGC018 (vobramitamab duocarmazine), CAN-2409, KPG-121, 177Lu-PNT2002 (PNT2002), Capivasertib, CAN-2409 + valacyclovir + radiation therapy ± ADT, MGC018, EPI-7386, and others

• Prostate Cancer Therapeutic Assessment: Prostate Cancer current marketed and Prostate Cancer emerging therapies

• Prostate Cancer Market Dynamics: Prostate Cancer market drivers and Prostate Cancer market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Prostate Cancer Unmet Needs, KOL’s views, Analyst’s views, Prostate Cancer Market Access and Reimbursement 

To know more about Prostate Cancer companies working in the treatment market, visit @ Prostate Cancer Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Prostate Cancer Market Report Introduction

2. Executive Summary for Prostate Cancer

3. SWOT analysis of Prostate Cancer

4. Prostate Cancer Patient Share (%) Overview at a Glance

5. Prostate Cancer Market Overview at a Glance

6. Prostate Cancer Disease Background and Overview

7. Prostate Cancer Epidemiology and Patient Population

8. Country-Specific Patient Population of Prostate Cancer 

9. Prostate Cancer Current Treatment and Medical Practices

10. Prostate Cancer Unmet Needs

11. Prostate Cancer Emerging Therapies

12. Prostate Cancer Market Outlook

13. Country-Wise Prostate Cancer Market Analysis (2020–2034)

14. Prostate Cancer Market Access and Reimbursement of Therapies

15. Prostate Cancer Market Drivers

16. Prostate Cancer Market Barriers

17.  Prostate Cancer Appendix

18. Prostate Cancer Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Prostate Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | Bayer, Johnson & Johnson Innovative Medicine (Janssen), Astellas Pharma, Pfizer, Janssen R&D